Organon & Co. Plans Quarterly Dividend of $0.02 (NYSE:OGN)

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Thursday, April 30th. Shareholders of record on Monday, May 11th will be paid a dividend of 0.02 per share on Thursday, June 11th. This represents a c) dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, May 11th.

Organon & Co. has a dividend payout ratio of 2.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $3.44 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.3%.

Organon & Co. Price Performance

Shares of NYSE OGN opened at $13.27 on Friday. The firm has a market capitalization of $3.48 billion, a P/E ratio of 18.68, a P/E/G ratio of 1.23 and a beta of 0.67. The company has a quick ratio of 1.23, a current ratio of 1.82 and a debt-to-equity ratio of 11.47. The stock’s 50-day simple moving average is $7.68 and its two-hundred day simple moving average is $7.76. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.39.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, May 7th. The company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.Organon & Co.’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.02 earnings per share. As a group, equities analysts anticipate that Organon & Co. will post 3.23 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on OGN shares. Barclays upped their target price on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 24th. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $5.00 to $14.00 in a research note on Tuesday. BNP Paribas Exane reaffirmed a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research report on Wednesday. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Finally, Wall Street Zen lowered Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Four equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Organon & Co. has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.